Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript

Ananda Ghosh: Yeah, hi. And so just wanted to get your opinion on some of these concepts which I don’t think the street understands very well with respect to the Aria focus program. So what has been, how do we think that the PUC, the C-Max and in a relative fractional occupancy when you are looking at data which comes from the kind of a subcutaneous data and with respect to your idea on the PRX drug development program. So any ideas with respect to those two factors would be very helpful to understand how to think about PRX12 development going forward. Thank you.

Gene Kinney : Yeah, no. I appreciate the question and it’s an important question and you talked about lecanemab and – and think their relevance as immuno is targeting anti beta antibodies and I think what we see with those antibodies as you look to the Phase 2 dataset and into the Phase 3 data set, is a relationship between removal of plaque and the dose response. So our exposure response relationship. So and in the case of lecanemab and I that relationship is close to linear. That’s not true with every anti beta antibody other antibodies show a much more of an all or none effect. And I pointed to – from that perspective around plaque clearance. I think with respect to Aria, it’s a little bit different. It is a little bit more molecule-dependent.

Although, that being said, there clearly as if those effect relationship within molecules, but between molecules, there’s a little bit of a difference and we continue to believe that Aria is a mechanistically-driven event meaning if you are removing plaque, you’re going to increase the risk of this observing Aria. But as I said their relationship between that and difference between antibodies may be a little bit different. So what we need to be informed by now is our data from multiple dose level cohorts from our ongoing Phase 1 trial. So that we can better characterize the relationship between PRX12 exposure and Aria rates. And we think that as we collect additional dose level cohorts data and as we think about the future substantive data updates, we would be able to talk in more detail about what that means specifically for PRX12.

Operator: Thank you, everyone. This is the this is all the time we have today. I’ll now turn it over to Gene Kinney, Chief Executive Officer for closing remarks.

Gene Kinney: Thank you very much operator and I want to thank you all for joining us on the call today. We appreciate your interest in Prothena and we look very much forward to sharing further updates on our program. Have a good afternoon.

Operator: Thank you for participating in today’s conference call. This concludes the presentation and you may now disconnect. Good day.